Pharmazz, Inc.
13
5
5
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
46%
6 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS
Role: lead
A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients
Role: lead
Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
Role: lead
Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Role: lead
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Role: lead
A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent
Role: lead
PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury
Role: lead
PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients
Role: lead
Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke
Role: lead
PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease
Role: lead
Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock
Role: lead
PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock
Role: lead
A Study to Determine the Safety, Tolerability and Pharmacokinetics of PMZ-2010 (Centhaquin) in Healthy Volunteers
Role: lead
All 13 trials loaded